This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.View RXII key stats
RXi Pharmaceuticals Corp - RXII - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates RXi Pharmaceuticals Corp as a
Sell with a ratings score of E+.
Report Snippet: We rate RXI PHARMACEUTICALS CORP (RXII) a SELL. This is based on several weak investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, deteriorating net income and poor profit margins.